SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
First of its kind screening for Glaucoma at grass root level over 10k screened already
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Approval to dramatically change CAR-T therapies landscape
Subscribe To Our Newsletter & Stay Updated